1 – 10 of 10
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
20-Year Steady Increase in Survival of Adult Patients with Relapsed Philadelphia-Positive Acute Lymphoblastic Leukemia Post Allogeneic Hematopoietic Cell Transplantation
(
- Contribution to journal › Article
- 2018
-
Mark
Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML : A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT)
(
- Contribution to journal › Article
-
Mark
Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion
(
- Contribution to journal › Article
- 2017
-
Mark
Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia : a study on behalf of the Acute Leukemia Working Party of the EBMT
(
- Contribution to journal › Article
- 2015
-
Mark
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
(
- Contribution to journal › Article
-
Mark
Outcome and risk factor analysis of molecular subgroups in cytogenetically normal AML treated by allogeneic transplantation.
(
- Contribution to journal › Article
- 2011
-
Mark
Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
(
- Contribution to journal › Article
- 2009
-
Mark
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.
(
- Contribution to journal › Article
-
Mark
Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse
(
- Contribution to journal › Published meeting abstract